Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain.

ABSTRACT: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads worldwide and leads to an unprecedented medical burden and lives lost. Neutralizing antibodies provide efficient blockade for viral infection and are a promising category of biological therapies. Here, using SARS-CoV-2 spike receptor-binding domain (RBD) as a bait, we generate a panel of humanized single domain antibodies (sdAbs) from a synthetic library. These sdAbs reveal binding kinetics with the equilibrium dissociation constant (KD) of 0.99-35.5?nM. The monomeric sdAbs show half maximal neutralization concentration (EC50) of 0.0009-0.07?µg/mL and 0.13-0.51?µg/mL against SARS-CoV-2 pseudotypes, and authentic SARS-CoV-2, respectively. Competitive ligand-binding experiments suggest that the sdAbs either completely block or significantly inhibit the association between SARS-CoV-2 RBD and viral entry receptor ACE2. Fusion of the human IgG1 Fc to sdAbs improve their neutralization activity by up to ten times. These results support neutralizing sdAbs as a potential alternative for antiviral therapies.

SUBMITTER: Chi X 

PROVIDER: S-EPMC7483421 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature